SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : HYDI: Hydromer, Inc.
HYDI 0.1100.0%Jan 9 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: GARY P GROBBEL2/15/2001 1:40:42 PM
   of 2
 
this a few days ago then a new one today...this is a BUY...trading around 1.00...4.6m outstanding:

(COMTEX) B: HYDROMER INC - Earnings for the First Quarter Ended Decem
B: HYDROMER INC - Earnings for the First Quarter Ended December 31, 2000.

New York, New York, Feb 13, 2001 (Market News Publishing via COMTEX) --
Hydromer, Inc. is pleased to report that the Company's revenues for the quarter
ended December 31, 2000 were $1,623,718 as compared to $724,127 for the same
period last year, or an increase of 124.2%.

Revenues for the Fiscal 2001 through 12/31/00 are $2,905,237, up 98% versus
$1,467,614 last fiscal year. These results include revenue from the Biosearch
Medical Products subsidiary, acquired in a cash transaction in February 2000.
Net earnings were up 66.3% to $189,368 for the quarter ended 12/31/00 as
compared to $84,089 reported for the quarter ending 12/31/99. Earnings per share
were $0.041 per share for the 2nd quarter, up 128%, as compared to $0.018 for
2nd quarter last year. Net Earnings YTD are $306,463 or $0.067 per share, versus
$184,295 or $0.04 for the same period last year.

Product, service and technology sales were up 405% to $1,022,259 in the second
quarter versus $202,575 in the same period last year, and $1,751,988 for the
six-month period ending 12/31/00 versus $314,766 for the same period last year.
Biosearch contributed $688,635 in revenue for the quarter, and $1,153,908
through the six-month period ending 12/31/00. Royalty, license and option
revenue increased 15.3% to $601,459 from $521,522 for the period ending December
31,2000 versus the same period last year.

The Company's gross profit was up 78.6% to $1,184,043 from $663,065 for the same
period last year. For the six-month period ending 12/31/00, the Company has
recorded a 62.4% increase in gross profit to $2,170,355 versus $1,336,504 from
the same period last year. Income before taxes was also up 145% to $296,720 for
the quarter from the prior years results of $121,089 for the same period. Year
to date, the Company's income before taxes is up 66.5% to $454,750 from $273,089
last fiscal year.

"We continue to see an acceleration in growth across many of our business areas,
and an improvement in profitability from our consolidations efforts," said
Manfred Dyck, President and CEO of Hydromer. "Our T-HEXX(R) Animal Health brand
is expanding its licensee base and distribution network here in North America
and in Europe. Our T-HEXX products are developing a strong following,
demonstrating their viability versus products offered by competitors like
Alcide's UdderGold(R) (NasdaqNM:ALCD) and Ecolab's Valiant(R) (NYSE:ECL) among
premium teat care users. Our Biosearch subsidiary is now contributing growth to
our top, and more importantly bottom line. We are continuing to aggressively
pursue additional license and new product opportunities to leverage our
technologies and process capabilities on a global basis, in addition to
increasing our presence in the medical products and animal health areas via
increased investment in advertising, promotion, and exhibits. The Company is
also continuing to make additional investments in technology, process
capabilities and facilities to offer and extended range of products and services
to the medical device community."

Hydromer, Inc. is a technology-based company involved in the research and
development and manufacture of specialized polymer and hydrogel products for
medical device, cosmetic, animal health, pharmaceutical, biotechnology and
industrial uses. Visit our corporate web site at: hydromer.com or
T-HEXX at www.T-HEXX.com.


CONTACT: TEL: 908/526-2828 Hydromer, Inc., Branchburg
Joseph Ehrhard

MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041.

(C) 2001 Market News Publishing Inc.

-0-


KEYWORD: New York, New York

*** end of story ***
(COMTEX) B: Hydromer, Inc. Announces License Agreement of T-HEXX in W
B: Hydromer, Inc. Announces License Agreement of T-HEXX in Western Europe

BRANCHBURG, N.J., Feb 15, 2001 (BUSINESS WIRE) -- Today, Hydromer, Inc. (OTC
BB: HYDI.OB) announced the signing of a license and supply agreement with
Kleencare Hygiene for Hydromer's patented T-HEXX(R) ORO(TM) Barrier Teat Dip for
the treatment and prevention of mastitis in dairy cattle.

Under the agreement, Kleencare will manufacture, distribute and sell T-HEXX ORO
under a non-exclusive license in Western Europe Hydromer will supply the
patented T-HEXX Barrier concentrate, and provide marketing and technical support
as it does with its current North American licensees.

"Mastitis prevention is a global opportunity," said Joseph Ehrhard, Vice
President of New Business and R&D at Hydromer, Inc. " European farmers face the
same challenges as their US counterparts, reducing costs and improving yields.
T-HEXX barrier products offer a unique combination of superior teat protection
and reduced waste, in an easy to use, one part system without excessive waste
like some competitive products. Kleencare Hygiene, being one of the leading
providers in Western Europe of cleaning and sanitization technology, recognized
the value of our T-HEXX barrier technology, particularly in the emerging premium
teat dip segment. They have been working with us for almost two years to field
and market test the product in their territory. Their manufacturing and
distribution systems will allow us to compete with the other major European
marketers, Ecolab-Henkel (NYSE:ECL) and Diversey-Lever, a division of Unilever
(NYSE:UL), and Alcide (NasdaqNM: ALCD."

"Our agreement with Kleencare is another step in the global rollout of our
T-HEXX technology, increasing our licensee and manufacturing base on T-HEXX
products to three parties" said Manfred Dyck, President and CEO of Hydromer. "
We will continue to seek out licensing and distribution partners to expand the
T-HEXX business, in addition to rolling out new, innovative products like
T-HEXX(R) Dry(TM), our product for dry cow mastitis prevention into the global
market."

Hydromer, Inc. is a technology-based company involved in the research and
development and manufacture of specialized polymer and hydrogel products for
medical device, pharmaceutical, animal health, cosmetic, personal care, and
industrial uses. Please visit our web site at www.hydromer.com or visit the
T-HEXX site at www.T-HEXX.com

Kleencare Hygiene is the largest independent hygiene company in Europe.
Kleencare Hygiene specializes in services, products and systems designed to meet
the hygiene needs of the total food and beverage industry from the farm through
processing to retail & catering. Their website can be found at www.kleencare.com


CONTACT: Hydromer, Inc., Branchburg
Joseph Ehrhard, 908/526-2828

URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.

-0-


KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: MANUFACTURING
MEDICAL
DEVICES
PHARMACEUTICAL
MARKETING
AGREEMENTS

*** end of story ***
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext